{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Control+label&page=2", "query": { "intervention": "Control label", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Control+label&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-04T17:04:13.269Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03633708", "title": "A Trial of Etelcalcetide in Pediatric Participants With Secondary Hyperparathyroidism and Chronic Kidney Disease on Hemodialysis", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Secondary Hyperparathyroidism", "Chronic Kidney Disease" ], "interventions": [ { "name": "Etelcalcetide", "type": "DRUG" }, { "name": "Standard of Care", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "0 Years", "maximum_age": "18 Years", "sex": "ALL", "summary": "0 Years to 18 Years" }, "enrollment_count": 56, "start_date": "2019-04-29", "completion_date": "2029-01-31", "has_results": false, "last_update_posted_date": "2026-02-27", "last_synced_at": "2026-09-04T17:04:13.269Z", "location_count": 10, "location_summary": "Los Angeles, California • Aurora, Colorado • Kansas City, Missouri + 7 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Kansas City", "state": "Missouri" }, { "city": "New York", "state": "New York" }, { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT03633708" }, { "nct_id": "NCT06072482", "title": "A Study to Evaluate Avacopan in Participants With ANCA-associated Vasculitis", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Antineutrophil Cytoplasmic Antibody-associated Vasculitis" ], "interventions": [ { "name": "Avacopan", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Standard of Care", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 300, "start_date": "2024-02-07", "completion_date": "2036-12-31", "has_results": false, "last_update_posted_date": "2026-08-14", "last_synced_at": "2026-09-04T17:04:13.269Z", "location_count": 62, "location_summary": "Anchorage, Alaska • Scottsdale, Arizona • Surprise, Arizona + 57 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Surprise", "state": "Arizona" }, { "city": "Searcy", "state": "Arkansas" }, { "city": "Covina", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06072482" }, { "nct_id": "NCT07169279", "title": "Interventional Study of Infigratinib in Children < 3 Years Old With Achondroplasia (ACH)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Achondroplasia" ], "interventions": [ { "name": "Infigratinib is provided as a single dose of minitablets for oral administration", "type": "DRUG" }, { "name": "Infigratinib is provided as sprinkle capsules for daily oral administration", "type": "DRUG" }, { "name": "Infigratinib or placebo comparator is provided as sprinkle capsules for daily oral administration", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "QED Therapeutics, a BridgeBio company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "0 Years", "maximum_age": "32 Months", "sex": "ALL", "summary": "0 Years to 32 Months" }, "enrollment_count": 77, "start_date": "2025-11-19", "completion_date": "2032-03", "has_results": false, "last_update_posted_date": "2026-07-13", "last_synced_at": "2026-09-04T17:04:13.269Z", "location_count": 3, "location_summary": "Oakland, California • Baltimore, Maryland • Madison, Wisconsin", "locations": [ { "city": "Oakland", "state": "California" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT07169279" }, { "nct_id": "NCT03452189", "title": "The Effect of an Antibiotic on the Production of Uremic Toxins by the Gut Microbiome", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "End Stage Renal Disease" ], "interventions": [ { "name": "Vancomycin", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "NYU Langone Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 15, "start_date": "2017-11-27", "completion_date": "2018-08-18", "has_results": true, "last_update_posted_date": "2021-03-26", "last_synced_at": "2026-09-04T17:04:13.269Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03452189" }, { "nct_id": "NCT01268618", "title": "Trenev Trio/Healthy Trinity for Symptoms of Diarrhea-predominant Irritable Bowel Syndrome (IBS) and Functional Dyspepsia", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "IBS-D and Functional Dyspepsia" ], "interventions": [ { "name": "Probiotic", "type": "DIETARY_SUPPLEMENT" }, { "name": "Placebo", "type": "DIETARY_SUPPLEMENT" } ], "intervention_types": [ "DIETARY_SUPPLEMENT" ], "sponsor": "Sprim Advanced Life Sciences", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 120, "start_date": "2011-01", "completion_date": "2011-08", "has_results": false, "last_update_posted_date": "2011-07-21", "last_synced_at": "2026-09-04T17:04:13.269Z", "location_count": 2, "location_summary": "Duluth, Georgia • Norfolk, Virginia", "locations": [ { "city": "Duluth", "state": "Georgia" }, { "city": "Norfolk", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01268618" }, { "nct_id": "NCT04663282", "title": "A Trial of INS068 in Patients With Type 2 Diabetes Not Adequately Controlled With One or Two Oral Antidiabetics", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Type 2 Diabetes" ], "interventions": [ { "name": "INS068 injection", "type": "DRUG" }, { "name": "Insulin Degludec", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Jiangsu HengRui Medicine Co., Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 179, "start_date": "2021-02-04", "completion_date": "2022-05-28", "has_results": false, "last_update_posted_date": "2022-12-21", "last_synced_at": "2026-09-04T17:04:13.269Z", "location_count": 15, "location_summary": "Huntington Park, California • Lincoln, California • Lomita, California + 10 more", "locations": [ { "city": "Huntington Park", "state": "California" }, { "city": "Lincoln", "state": "California" }, { "city": "Lomita", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Cooper City", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04663282" }, { "nct_id": "NCT06473779", "title": "Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma.", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Severe Asthma" ], "interventions": [ { "name": "Tezepelumab", "type": "COMBINATION_PRODUCT" }, { "name": "Budesonide/formoterol", "type": "COMBINATION_PRODUCT" }, { "name": "Albuterol/budesonide (AIRSUPRA®)", "type": "COMBINATION_PRODUCT" }, { "name": "Mannitol", "type": "COMBINATION_PRODUCT" }, { "name": "Salbutamol", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "COMBINATION_PRODUCT" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "12 Years to 80 Years" }, "enrollment_count": 326, "start_date": "2024-09-30", "completion_date": "2027-06-25", "has_results": false, "last_update_posted_date": "2026-06-15", "last_synced_at": "2026-09-04T17:04:13.269Z", "location_count": 8, "location_summary": "Palmdale, California • Colorado Springs, Colorado • Miami, Florida + 5 more", "locations": [ { "city": "Palmdale", "state": "California" }, { "city": "Colorado Springs", "state": "Colorado" }, { "city": "Miami", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT06473779" }, { "nct_id": "NCT03509350", "title": "Vitamin C, Thiamine, and Steroids in Sepsis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Sepsis" ], "interventions": [ { "name": "Vitamin C", "type": "DRUG" }, { "name": "Thiamine", "type": "DRUG" }, { "name": "Hydrocortisone", "type": "DRUG" }, { "name": "Vitamin C Placebo", "type": "DRUG" }, { "name": "Thiamine Placebo", "type": "DRUG" }, { "name": "Hydrocortisone Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 501, "start_date": "2018-08-22", "completion_date": "2020-01-29", "has_results": true, "last_update_posted_date": "2021-04-13", "last_synced_at": "2026-09-04T17:04:13.269Z", "location_count": 43, "location_summary": "Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 30 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT03509350" }, { "nct_id": "NCT02059291", "title": "Study of Efficacy and Safety of Canakinumab in Patients With Hereditary Periodic Fevers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hereditary Periodic Fevers" ], "interventions": [ { "name": "Canakinumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Month", "maximum_age": null, "sex": "ALL", "summary": "1 Month and older" }, "enrollment_count": 203, "start_date": "2014-06-27", "completion_date": "2017-07-04", "has_results": true, "last_update_posted_date": "2018-05-17", "last_synced_at": "2026-09-04T17:04:13.269Z", "location_count": 3, "location_summary": "Los Angeles, California • Ann Arbor, Michigan • Cleveland, Ohio", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT02059291" }, { "nct_id": "NCT01596920", "title": "Grafix® DFU: Open-Label Extension Option to Evaluate Safety & Efficacy of Grafix® for Chronic Diabetic Foot Ulcers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Diabetic Foot Ulcers" ], "interventions": [ { "name": "Tissue", "type": "OTHER" }, { "name": "Control", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Osiris Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 97, "start_date": "2012-04", "completion_date": "2014-03", "has_results": false, "last_update_posted_date": "2014-04-09", "last_synced_at": "2026-09-04T17:04:13.269Z", "location_count": 15, "location_summary": "Montgomery, Alabama • Glendale, Arizona • Encinitas, California + 12 more", "locations": [ { "city": "Montgomery", "state": "Alabama" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Encinitas", "state": "California" }, { "city": "Inverness", "state": "Florida" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01596920" } ] }